Investment Analysts’ Recent Ratings Updates for Avidity Biosciences (RNA)

Several analysts have recently updated their ratings and price targets for Avidity Biosciences (NASDAQ: RNA):

• 5/30/2026 – Avidity Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/22/2026 – Avidity Biosciences was downgraded by Weiss Ratings from “sell (d-)” to “sell (e-)”.
• 5/16/2026 – Avidity Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/15/2026 – Avidity Biosciences is now covered by Leerink Partners. They set an “outperform” rating on the stock.
• 5/1/2026 – Avidity Biosciences had its “neutral” rating reaffirmed by HC Wainwright.

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study.